HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing's disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone.

AbstractCONTEXT:
Pituitary effects of long-term therapy with mifepristone, a glucocorticoid receptor antagonist, in Cushing's disease (CD) patients are not well understood.
OBJECTIVE:
Our objective was to report changes in ACTH and pituitary magnetic resonance imaging (MRI) findings during long-term use of mifepristone in CD patients.
DESIGN AND SETTING:
The Study of the Efficacy and Safety of Mifepristone in the Treatment of Endogenous Cushing's Syndrome (SEISMIC) was a 24-week, open-label study of mifepristone, and its long-term extension (LTE) is a multicenter U.S. study.
PATIENTS:
Forty-three CD patients (mean age 45.3 years) were enrolled in SEISMIC with 27 continuing into the LTE study.
INTERVENTIONS:
Mifepristone (300-1200 mg) was administered once daily.
MAIN OUTCOME MEASURES:
ACTH and pituitary MRI were assessed at baseline and at regular intervals during treatment.
RESULTS:
A ≥2-fold increase in ACTH was observed in 72% of patients treated for a median duration of 11.3 months. The mean peak increase in ACTH was 2.76 ± 1.65-fold during SEISMIC, and mean ACTH concentrations remained stable during the LTE. ACTH was directly correlated with mifepristone dose and declined to near baseline levels after mifepristone discontinuation. Tumor regressed in 2 patients and progressed in 3 patients with macroadenomas. An additional microadenoma was identified after 25 months of treatment after a baseline tumor-negative MRI.
CONCLUSIONS:
In the largest prospective study to date, long-term mifepristone treatment increased ACTH in approximately two-thirds of patients with CD. ACTH elevations were observed within the first few weeks of treatment, were dose-dependent, and generally remained stable over time. Corticotroph tumor progression and regression may occur over time, but patients may have significant increases in ACTH levels without evidence of tumor growth.
AuthorsMaria Fleseriu, James W Findling, Christian A Koch, Sven-Martin Schlaffer, Michael Buchfelder, Coleman Gross
JournalThe Journal of clinical endocrinology and metabolism (J Clin Endocrinol Metab) Vol. 99 Issue 10 Pg. 3718-27 (Oct 2014) ISSN: 1945-7197 [Electronic] United States
PMID25013998 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Hormone Antagonists
  • Receptors, Glucocorticoid
  • Mifepristone
  • Adrenocorticotropic Hormone
  • Hydrocortisone
Topics
  • Adenoma (drug therapy, metabolism, pathology)
  • Adrenocorticotropic Hormone (blood)
  • Adult
  • Corticotrophs (metabolism, pathology)
  • Female
  • Hormone Antagonists (administration & dosage, adverse effects)
  • Humans
  • Hydrocortisone (blood)
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Mifepristone (administration & dosage, adverse effects)
  • Pituitary ACTH Hypersecretion (drug therapy, metabolism, pathology)
  • Pituitary Neoplasms (drug therapy, metabolism, pathology)
  • Prospective Studies
  • Receptors, Glucocorticoid (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: